Jak Jnhibitors

Question 1

What is the generic name and brand name for the JAK-1 inhibitors?

Answer 1

Upadacitinib (Rinvoq)
Abrocitinib (cibinqo)

JAK-1 inhibitors target Janus kinase 1, involved in signaling pathways related to immune responses.

Question 2

What is the mechanism of action for Abrocitinib (cibinqo)?

Answer 2

JAK-1 Inhibitor

Abrocitinib is used for treating atopic dermatitis.

Question 3

What conditions is Baricitinib (olumiant) approved for?

Answer 3

Severe Alopecia Areata,

Rheumatoid Arthritis, COVID-19 in hospitalized adults

Baricitinib is a JAK-1/2 inhibitor.

Question 4

What is the FDA-approved age for Ritlecitinib (litfulo) usage? And what is it FDA approved for?

Answer 4

≥12 years

Ritlecitinib is used for severe alopecia areata.

Question 5

Which JAK inhibitor is indicated for Psoriatic Arthritis?

Answer 5

Tofacitinib (Xeljanz)

Tofacitinib is a JAK-1/3 inhibitor.

Question 6

What is the mechanism of action for Deucravacitinib?

Answer 6

Tyrosine Kinase 2 (TYK2) Inhibitor

TYK2 inhibitors block a pathway involved in inflammatory responses.

Question 7

What is the
dosing for Ruxolitinib (opzelura) topical cream? And what is it FDA approved for?

Answer 7

Apply 1.5% cream topically BID

Ruxolitinib is used for vitiligo (>12yoa) and atopic dermatitis (>12yoa).

Question 8

What is the initial monitoring required for Baricitinib?

Answer 8

TB, CBC w/diff., CMP, Lipids, Viral Hepatitis Screening, Pregnancy, HIV, Vaccinations

Regular monitoring helps manage potential adverse effects.

Question 9

What should be considered when dosing Upadacitinib (rinvoq) in patients with inadequate response?

Answer 9

Consider increasing to 30 mg PO QD

This is FDA approved for atopic dermatitis

Others: IBD, ankylosis spondylitis, psoriatic arthritis

Adjustments depend on clinical response and safety.

Question 10

True or False: Baricitinib can be used in patients with severe hepatic impairment.

Answer 10

False

Severe hepatic impairment is a contraindication for Baricitinib.

Question 11

What other conditions can Tofacitinib (xeljanz) treat besides Psoriatic Arthritis?

Answer 11

Rheumatoid Arthritis, Ankylosing Spondylitis, Ulcerative Colitis, Polyarticular Course Juvenile Idiopathic Arthritis

Tofacitinib has multiple indications beyond PsA.

Question 12

Fill in the blank: The dosing of Deucravacitinib is _______.

Answer 12

6 mg PO QD
No other dosing

Deucravacitinib is used for psoriasis.

Question 13

What is the follow-up recommendation for initial monitoring of topical Ruxolitinib (opzelura)?

Answer 13

None.
No routine lab monitoring is required.
This is for a topic dermatitis and can treat up to 20% BSA for vitiligo up to 10% BSA

Question 14

What is the recommended dose adjustment for patients with nearly complete to complete hair loss when using baricitinib (olumiant)?

Answer 14

Consider treating with 4 mg QD

Dose adjustments are based on clinical efficacy.